Table 3.
Datasets | Phase | AUC (95% CI) | p-value | Sensitivity (%) | Specificity (%) | Accuracy (%) |
---|---|---|---|---|---|---|
Cohort 1 | NP | 0.898 (0.863–0.932) | 0.003* | 100.0 | 63.9 | 72.7 |
AP | 0.735 (0.653–0.817) | <0.001* | 51.9 | 83.1 | 75.5 | |
PVP | 0.756 (0.690–0.822) | <0.001* | 81.5 | 61.4 | 66.4 | |
mp-CT | 0.941 (0.909–0.973) | Ref. | 88.9 | 83.1 | 84.5 | |
Cohort 2 | NP | 0.680 (0.631–0.730) | <0.001* | 76.9 | 57.1 | 61.8 |
AP | 0.769 (0.718–0.820) | 0.026* | 69.2 | 73.8 | 72.7 | |
PVP | 0.734 (0.686–0.783) | <0.001* | 76.9 | 57.1 | 61.8 | |
mp-CT | 0.833 (0.798–0.868) | Ref. | 76.9 | 71.4 | 72.7 |
p-values were analyzed by the Delong test.
AUC, area under the curve; CI, confidence interval; NP, noncontrast phase; AP, arterial phase; PVP, portal venous phase; mp-CT, multiple-phase CT.